These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 21289267)

  • 1. The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.
    Liu R; Liu D; Trink E; Bojdani E; Ning G; Xing M
    J Clin Endocrinol Metab; 2011 Apr; 96(4):E577-85. PubMed ID: 21289267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.
    Liu D; Hou P; Liu Z; Wu G; Xing M
    Cancer Res; 2009 Sep; 69(18):7311-9. PubMed ID: 19706758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells.
    Liu R; Liu D; Xing M
    J Clin Endocrinol Metab; 2012 Feb; 97(2):E173-82. PubMed ID: 22090271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
    Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
    Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
    Grabinski N; Ewald F; Hofmann BT; Staufer K; Schumacher U; Nashan B; Jücker M
    Mol Cancer; 2012 Nov; 11():85. PubMed ID: 23167739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway.
    Xu R; Zhang Y; Li A; Ma Y; Cai W; Song L; Xie Y; Zhou S; Cao W; Tang X
    Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33982772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus.
    Liu D; Xing J; Trink B; Xing M
    Int J Cancer; 2010 Dec; 127(12):2965-73. PubMed ID: 21351275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures.
    Narayan RS; Fedrigo CA; Brands E; Dik R; Stalpers LJ; Baumert BG; Slotman BJ; Westerman BA; Peters GJ; Sminia P
    BMC Cancer; 2017 Mar; 17(1):204. PubMed ID: 28320338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
    Xing M
    Thyroid; 2010 Jul; 20(7):697-706. PubMed ID: 20578891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probing the PI3K/Akt/mTor pathway using
    Phyu SM; Tseng CC; Fleming IN; Smith TA
    Sci Rep; 2016 Nov; 6():36544. PubMed ID: 27811956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional characterization of PI3K C2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells.
    Smit DJ; Brauer H; Horn S; Yigit G; Haider MT; Pogenberg V; Schumacher U; Pantel K; Jücker M
    Cell Signal; 2024 Sep; 121():111270. PubMed ID: 38909932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.
    Xu S; Li S; Guo Z; Luo J; Ellis MJ; Ma CX
    Mol Cancer Ther; 2013 Aug; 12(8):1665-75. PubMed ID: 23689832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
    Yi YW; Kang HJ; Kim HJ; Hwang JS; Wang A; Bae I
    Mol Carcinog; 2013 Sep; 52(9):667-75. PubMed ID: 22488590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors.
    Wang Y; Hou P; Yu H; Wang W; Ji M; Zhao S; Yan S; Sun X; Liu D; Shi B; Zhu G; Condouris S; Xing M
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2387-90. PubMed ID: 17426084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma.
    Milosevic Z; Pesic M; Stankovic T; Dinic J; Milovanovic Z; Stojsic J; Dzodic R; Tanic N; Bankovic J
    Transl Res; 2014 Nov; 164(5):411-23. PubMed ID: 25016932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways.
    Kandil E; Tsumagari K; Ma J; Abd Elmageed ZY; Li X; Slakey D; Mondal D; Abdel-Mageed AB
    J Surg Res; 2013 Oct; 184(2):898-906. PubMed ID: 23602735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.
    Beaver JA; Gustin JP; Yi KH; Rajpurohit A; Thomas M; Gilbert SF; Rosen DM; Ho Park B; Lauring J
    Clin Cancer Res; 2013 Oct; 19(19):5413-22. PubMed ID: 23888070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resveratrol potentiates the anti-tumor effects of rapamycin in papillary thyroid cancer: PI3K/AKT/mTOR pathway involved.
    Bian P; Hu W; Liu C; Li L
    Arch Biochem Biophys; 2020 Aug; 689():108461. PubMed ID: 32531316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.
    Meng J; Dai B; Fang B; Bekele BN; Bornmann WG; Sun D; Peng Z; Herbst RS; Papadimitrakopoulou V; Minna JD; Peyton M; Roth JA
    PLoS One; 2010 Nov; 5(11):e14124. PubMed ID: 21124782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
    Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.